Will New Trial Solution Data Spark a Rally for this Dual-Listed Gen AI Clinical Trial Leader?

Sponsored:

Thursday, February 29, 2024

Parkinson’s disease is a complex and debilitating disease with a need for novel treatment options. This firm’s goal is to advance its understanding of the biological markers and pathways that contribute to the development and progression of the disease — and they plan to share these findings at an upcoming conference.

Generative AI software leader in clinical trial analytics, NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF)  announced in a press release today that it will present new data demonstrating the potential of its proprietary NetraAI clinical trial solution to generate novel insights into key drivers of Parkinson's disease.

NetraMark focuses on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry, using a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. By using a variety of ML methods, depending on the character and size of the data, the firm transforms the data into powerfully intelligent data that activates traditional AI/ML methods, resulting in the ability to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

In morning trade, U.S. shares were flat, and Canadian-listed shares were trading down. 

Sponsored: